Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City Phase 1, Bengaluru, Karnataka, 560100, India.
Orphanet J Rare Dis. 2019 May 29;14(1):117. doi: 10.1186/s13023-019-1093-6.
Rare diseases (RDs) affect a small percentage of the population but can be severely debilitating and life-threatening. Historically, patient groups (PGs) have been the prime movers in raising awareness about these diseases and advocating for national supportive policies. They have also driven relevant research programs. In India too, PGs have made significant contributions to the national RD ecosystem.
To assess the contribution of various Indian RD PGs, we carried out an interview-based study of 19organizations. This study aims to highlight the origins and achievements of these groups and the challenges that they have faced. The study also helps to capture the changes in the RD ecosystem that have taken place in recent years.
Of the 19 PGs, two are umbrella organizations, two are other organizations of national scope and 15 are disease specific groups. 14 interviewees were affected by an RD either directly or through a family member. Lack of awareness about RDs in the medical community was the biggest challenge, leading to a delay in diagnosis and subsequent management. Only two out of the 15 conditions have a definitive treatment. However, many of the diseases can be managed with replacement therapies administered for the patient's entire life, or other supportive therapies. Most diagnostics and treatment regimens that are available globally are now available in India but are expensive and usually available only in a few major cities. These problems are compounded by a lack of medical insurance schemes and government policies to support these patients. The biggest achievement of the PGs was the passing of National Policy for Treatment of Rare Diseases in 2017, unfortunately since put in abeyance. If reinstated, and properly implemented, this policy could significantly improve RD management in the country.
PGs have had a significant role in bringing diagnostics and treatments to India. They have also raised awareness about RDs and related issues such as newborn screening, prenatal diagnostics and genetic counselling. This study highlighted the recommendations of various PGs. The government should address these recommendations and institutionalize the participation of the PGs in formal decision making.
罕见病(RDs)影响一小部分人口,但可能会导致严重的身体残疾和危及生命。历史上,患者群体(PGs)一直是提高对这些疾病认识和倡导国家支持政策的主要推动者。他们还推动了相关的研究计划。在印度,PGs 也为国家 RD 生态系统做出了重大贡献。
为了评估各种印度 RD PGs 的贡献,我们对 19 个组织进行了基于访谈的研究。本研究旨在强调这些团体的起源和成就,以及他们所面临的挑战。该研究还帮助捕捉了近年来 RD 生态系统发生的变化。
在 19 个 PGs 中,有两个是伞式组织,两个是具有全国范围的其他组织,还有 15 个是特定疾病的组织。14 名受访者直接或通过家庭成员受到 RD 的影响。医学社区对 RDs 的认识不足是最大的挑战,导致诊断和后续管理的延迟。在 15 种疾病中只有两种有明确的治疗方法。然而,许多疾病可以通过终身给予患者替代疗法或其他支持性疗法来进行管理。现在,印度可以获得全球范围内的大多数诊断和治疗方案,但这些方案价格昂贵,通常只在少数几个主要城市提供。这些问题因缺乏医疗保险公司和政府支持这些患者的政策而更加复杂。PGs 的最大成就是在 2017 年通过了《罕见病治疗国家政策》,不幸的是,该政策目前已被搁置。如果该政策得到恢复并得到适当执行,它将大大改善印度的 RD 管理。
PGs 在将诊断和治疗引入印度方面发挥了重要作用。他们还提高了对 RDs 以及新生儿筛查、产前诊断和遗传咨询等相关问题的认识。本研究强调了各种 PGs 的建议。政府应解决这些建议,并将 PGs 的参与正式纳入决策制定过程。